PriceTargets.com logo

Deciphera Pharmaceuticals - DCPH Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $22.56
  • Forecasted Upside: 78.87%
  • Number of Analysts: 10
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$12.61 As of 11/30/2023 01:00 AM ET
▲ +0.21 (1.69%)

This chart shows the closing price for DCPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Deciphera Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCPH

Analyst Price Target is $22.56
▲ +78.87% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Deciphera Pharmaceuticals in the last 3 months. The average price target is $22.56, with a high forecast of $30.00 and a low forecast of $9.00. The average price target represents a 78.87% upside from the last price of $12.61.

This chart shows the closing price for DCPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 10 polled investment analysts is to moderate buy stock in Deciphera Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/8/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/6/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/5/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
6/3/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/1/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/31/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/20/2023JPMorgan Chase & Co.Reiterated RatingNeutral$14.00Low
10/31/2023Stifel NicolausBoost TargetBuy ➝ Buy$20.00 ➝ $22.00Low
10/31/2023JonestradingUpgradeHold ➝ BuyLow
10/31/2023HC WainwrightBoost TargetBuy ➝ Buy$25.00 ➝ $30.00Low
10/30/2023Piper SandlerUpgradeNeutral ➝ Overweight$18.00 ➝ $23.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00N/A
8/9/2023Stifel NicolausUpgradeHold ➝ Buy$14.00 ➝ $20.00Low
5/4/2023Stifel NicolausLower Target$17.00 ➝ $14.00Low
3/15/2023JMP SecuritiesReiterated RatingMarket Outperform$23.00Low
2/8/2023HC WainwrightReiterated RatingBuy$25.00Low
2/7/2023SVB LeerinkBoost TargetOutperform$28.00 ➝ $30.00Low
1/25/2023CowenBoost TargetOutperform$25.00 ➝ $30.00Low
1/6/2023JonestradingUpgradeSell ➝ HoldLow
1/4/2023SVB LeerinkBoost TargetOutperform$25.00 ➝ $28.00Low
1/4/2023BarclaysBoost TargetUnderweight$8.00 ➝ $9.00Low
1/4/2023GuggenheimUpgradeNeutral ➝ Buy$22.00Low
9/27/2022Stifel NicolausBoost TargetHold$11.00 ➝ $18.00Low
9/12/2022SVB LeerinkBoost TargetOutperform$21.00 ➝ $25.00Low
9/12/2022HC WainwrightBoost TargetBuy$20.00 ➝ $25.00Low
9/11/2022Piper SandlerBoost Target$13.00 ➝ $18.00Low
8/29/2022CowenInitiated CoverageOutperform$25.00Low
8/29/2022CowenInitiated CoverageOutperform$25.00Low
8/5/2022SVB LeerinkBoost TargetOutperform$15.00 ➝ $21.00Low
8/5/2022HC WainwrightBoost TargetBuy$15.00 ➝ $20.00Low
8/5/2022JMP SecuritiesUpgradeMarket Perform ➝ Outperform$23.00Low
2/28/2022BarclaysDowngradeEqual Weight ➝ Underweight$11.00 ➝ $6.00Low
12/1/2021HC WainwrightLower TargetBuy$25.00 ➝ $15.00High
11/30/2021Piper SandlerLower TargetNeutral$14.00 ➝ $11.00High
11/22/2021JonestradingReiterated RatingSellHigh
11/15/2021SVB LeerinkReiterated RatingBuy$70.00Medium
11/8/2021HC WainwrightLower TargetBuy$70.00 ➝ $25.00High
11/8/2021BarclaysDowngradeOverweight ➝ Equal Weight$50.00 ➝ $11.00High
11/7/2021Stifel NicolausDowngradeBuy ➝ Hold$60.00 ➝ $10.00High
11/5/2021Piper SandlerDowngradeOverweight ➝ NeutralN/A
11/5/2021GuggenheimDowngradeBuy ➝ NeutralN/A
11/5/2021Truist FinancialDowngradeBuy ➝ Hold$65.00 ➝ $10.00N/A
11/5/2021JMP SecuritiesLower TargetMarket Outperform$70.00 ➝ $64.00N/A
10/4/2021Truist FinancialLower TargetBuy$84.00 ➝ $65.00Medium
9/29/2021Stifel NicolausInitiated CoverageBuyLow
9/20/2021HC WainwrightReiterated RatingBuy$70.00Low
9/20/2021JMP SecuritiesReiterated RatingBuy$70.00Low
8/4/2021HC WainwrightLower TargetPositive ➝ Buy$75.00 ➝ $70.00High
5/5/2021HC WainwrightLower TargetBuy$80.00 ➝ $75.00High
5/5/2021BarclaysLower TargetOverweight$70.00 ➝ $65.00High
5/5/2021Piper SandlerLower TargetOverweight$75.00 ➝ $60.00High
3/30/2021Credit Suisse GroupInitiated CoverageOutperform$78.00High
2/10/2021BarclaysLower TargetOverweight$85.00 ➝ $70.00Low
2/10/2021SVB LeerinkUpgradeMarket Perform ➝ Outperform$70.00Low
12/2/2020Stifel NicolausInitiated CoverageBuy$75.00Medium
11/12/2020SVB LeerinkBoost TargetMarket Perform$58.00 ➝ $70.00Low
9/14/2020SVB LeerinkBoost TargetMarket Perform$54.00 ➝ $58.00Medium
9/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralHigh
8/5/2020SVB LeerinkLower TargetMarket Perform$55.00 ➝ $54.00Low
6/12/2020GuggenheimReiterated RatingBuy$70.00High
5/18/2020SunTrust BanksBoost TargetBuy$82.00 ➝ $91.00Medium
5/18/2020BarclaysReiterated RatingBuy$80.00 ➝ $85.00Medium
5/7/2020Nomura InstinetDowngradeBuy ➝ Neutral$84.00 ➝ $60.00Low
5/6/2020NomuraDowngradeBuy ➝ Neutral$84.00 ➝ $60.00Low
5/6/2020JPMorgan Chase & Co.Lower TargetOverweight$50.00 ➝ $49.00High
5/6/2020HC WainwrightBoost TargetBuy$60.00 ➝ $80.00High
4/29/2020SunTrust BanksBoost TargetBuy$77.00 ➝ $82.00Medium
4/29/2020SVB LeerinkBoost TargetHold$50.00 ➝ $55.00Medium
3/4/2020BarclaysInitiated CoverageOverweight$70.00High
1/22/2020Piper SandlerReiterated RatingBuy$75.00Low
1/21/2020Nomura SecuritiesBoost TargetBuy$57.00 ➝ $84.00Low
1/15/2020JMP SecuritiesReiterated RatingBuy$70.00Low
1/10/2020SunTrust BanksInitiated CoverageBuy$77.00Low
12/20/2019Piper Sandler CompaniesBoost TargetOverweight$55.00 ➝ $75.00Low
12/20/2019Jefferies Financial GroupBoost TargetBuy$53.00 ➝ $77.00Medium
11/5/2019JMP SecuritiesBoost TargetOutperform ➝ Market Outperform$45.00 ➝ $54.00Low
10/29/2019SVB LeerinkUpgradeUnderperform ➝ Market Perform$29.00 ➝ $34.00Medium
10/22/2019JMP SecuritiesInitiated CoverageOutperformLow
10/3/2019HC WainwrightInitiated CoverageBuy$60.00High
9/30/2019Piper Sandler CompaniesSet TargetBuy$55.00High
9/30/2019Jefferies Financial GroupInitiated CoverageBuy$47.00High
8/14/2019SunTrust BanksBoost TargetPositive ➝ Buy$60.00Low
8/14/2019SVB LeerinkReiterated RatingUnderperform ➝ Positive$20.00 ➝ $29.00High
8/14/2019Cantor FitzgeraldBoost TargetOverweight$43.00 ➝ $55.00High
8/13/2019GuggenheimBoost TargetBuy$44.00 ➝ $66.00High
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$42.00Low
6/3/2019Piper Sandler CompaniesBoost TargetOverweight$50.00 ➝ $55.00High
1/1/2019B. RileyDowngradeBuy ➝ NeutralHigh
12/31/2018B. RileyInitiated CoverageNeutral ➝ Buy$27.00 ➝ $34.00High
12/20/2018Cantor FitzgeraldReiterated RatingBuy$53.00Medium
(Data available from 11/30/2018 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/4/2023
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/3/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2023
  • 7 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
9/1/2023
  • 5 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
10/31/2023
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2023

Current Sentiment

  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Deciphera Pharmaceuticals logo
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $12.61
Low: $12.51
High: $12.90

50 Day Range

MA: $11.75
Low: $10.11
High: $13.25

52 Week Range

Now: $12.61
Low: $9.90
High: $22.76

Volume

655,230 shs

Average Volume

638,093 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?

The following Wall Street research analysts have issued reports on Deciphera Pharmaceuticals in the last year: Barclays PLC, Cowen Inc, Guggenheim, HC Wainwright, JMP Securities, Jonestrading, JPMorgan Chase & Co., Piper Sandler, Stifel Nicolaus, and SVB Leerink LLC.
View the latest analyst ratings for DCPH.

What is the current price target for Deciphera Pharmaceuticals?

9 Wall Street analysts have set twelve-month price targets for Deciphera Pharmaceuticals in the last year. Their average twelve-month price target is $22.56, suggesting a possible upside of 78.9%. SVB Leerink LLC has the highest price target set, predicting DCPH will reach $30.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $9.00 for Deciphera Pharmaceuticals in the next year.
View the latest price targets for DCPH.

What is the current consensus analyst rating for Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals currently has 1 sell rating, 1 hold rating and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DCPH.

What other companies compete with Deciphera Pharmaceuticals?

Other companies that are similar to Deciphera Pharmaceuticals include Ardelyx, Ligand Pharmaceuticals, Day One Biopharmaceuticals, MannKind and Protagonist Therapeutics. Learn More about companies similar to Deciphera Pharmaceuticals.

How do I contact Deciphera Pharmaceuticals' investor relations team?

Deciphera Pharmaceuticals' physical mailing address is 200 SMITH STREET, Waltham MA, 02451. The company's listed phone number is (781) 209-6400 and its investor relations email address is [email protected]. The official website for Deciphera Pharmaceuticals is www.deciphera.com. Learn More about contacing Deciphera Pharmaceuticals investor relations.